Reviewed Mar 2026 | Sources: PubMed

Semaglutide vs Liraglutide: Head-to-Head Comparison

Both are FDA-approved GLP-1 receptor agonists for diabetes and obesity. Semaglutide (Ozempic/Wegovy) is dosed weekly and produces greater weight loss (~15%). Liraglutide (Victoza/Saxenda) is dosed daily with more long-term safety data. Semaglutide has largely replaced liraglutide as first-line in clinical practice.

Side-by-Side Comparison

DimensionSemaglutideLiraglutide
Evidence LevelLevel A — multiple large RCTs (STEP, SUSTAIN, SELECT)Level A — multiple large RCTs (SCALE, LEADER)
FDA StatusApproved for T2D (Ozempic) and obesity (Wegovy)Approved for T2D (Victoza) and obesity (Saxenda)
Weight Loss Efficacy~15% mean body weight loss (STEP 1)~8% mean body weight loss (SCALE)
Dosing ConvenienceOnce weekly injection; oral option (Rybelsus)Daily injection required
Side EffectsGI side effects; similar profile but higher potencyGI side effects; well-characterized over 10+ years
Long-Term DataStrong CV data (SELECT); ~5 years post-approval10+ years of real-world data; LEADER CV benefit proven
Evidence Level
Semaglutide
Level A — multiple large RCTs (STEP, SUSTAIN, SELECT)
Liraglutide
Level A — multiple large RCTs (SCALE, LEADER)
FDA Status
Semaglutide
Approved for T2D (Ozempic) and obesity (Wegovy)
Liraglutide
Approved for T2D (Victoza) and obesity (Saxenda)
Weight Loss Efficacy
Semaglutide
~15% mean body weight loss (STEP 1)
Liraglutide
~8% mean body weight loss (SCALE)
Dosing Convenience
Semaglutide
Once weekly injection; oral option (Rybelsus)
Liraglutide
Daily injection required
Side Effects
Semaglutide
GI side effects; similar profile but higher potency
Liraglutide
GI side effects; well-characterized over 10+ years
Long-Term Data
Semaglutide
Strong CV data (SELECT); ~5 years post-approval
Liraglutide
10+ years of real-world data; LEADER CV benefit proven

Peptide Overviews

Semaglutide

AFDA Approved

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Weight LossFDA Approved
View full Semaglutide profile →

Liraglutide

AFDA Approved

Liraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It was the first GLP-1 agonist approved specifically for obesity.

Weight LossFDA Approved
View full Liraglutide profile →

Semaglutide vs Liraglutide: FAQ

Stay Informed on Peptide Research

Get weekly comparison updates, new study alerts, and regulatory changes.

No spam. Unsubscribe anytime.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.